{"id":"W4402565585","doi":"10.1016/j.annonc.2024.08.2311","title":"LBA68 Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Bayer HealthCare; Exelixis; American Society of Clinical Oncology; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001355711,0.0009177375,0.001620398,0.0002707057,0.0002942064,0.0009133688,0.0006517848,0.0007819743,0.005838424],"category_scores_gemma":[0.001244137,0.0003158022,0.001729014,0.0003635552,0.000568262,0.0007241537,0.0003792934,0.003418143,0.0009784097],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006181726,"about_ca_system_score_gemma":0.0009362271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008103591,"about_ca_topic_score_gemma":0.003360082,"domain_scores_codex":[0.9995827,0.000208229,0.00001951317,0.00005103343,0.00004356678,0.00009485072],"domain_scores_gemma":[0.9994408,0.0001493889,0.0001085529,0.00004523693,0.00004085877,0.0002151569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7829577,0.008370481,0.005733508,0.001654243,0.00284583,0.0002111066,0.0001491717,0.003113423,0.01504262,0.0008702573,0.01311155,0.1659401],"study_design_scores_gemma":[0.7589301,0.1984055,0.02258353,0.0002241849,0.002585389,0.0006096932,0.00009013324,0.001384139,0.002209968,0.0009715494,0.01193271,0.0000731291],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9760123,0.01096575,0.0004362742,0.001322742,0.0003795759,0.0006505823,0.00331195,0.0001530239,0.006767831],"genre_scores_gemma":[0.9819822,0.005156081,0.0009714514,0.001167024,0.0004130578,0.0005590391,0.005957295,0.00004449875,0.003749324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005838424,"threshold_uncertainty_score":0.01953149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06839710869532524,"score_gpt":0.4041756379512355,"score_spread":0.3357785292559103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}